Administration of cinacalcet in pediatric patients with CKD; a short-review on recent concepts

Cinacalcet shows promise in treating secondary hyperparathyroidism (sHPT) in both pediatric and adult chronic kidney disease (CKD) populations; however, its efficacy appears more pronounced in adults. Pediatric patients face unique challenges that can hinder treatment success, necessitating careful monitoring and individualized approaches to therapy. Further research is essential to optimize dosing strategies and improve outcomes for children receiving cinacalcet.